



Claudin18.2 is a member of Claudin family proteins, which are mainly expressed in epithelial cells, and their function is to regulate the permeability of barrier structures. The structure of Claudin18.2 protein is a four-pass transmembrane protein, as shown in the figure. Claudin18.2 is overexpressed in various malignant tumors, such as breast cancer, colon cancer, liver cancer, head and neck cancer, lung cancer, and especially in digestive system tumors, including gastric cancer (70%), pancreatic cancer (50%), esophageal cancer (30%), etc.




Claudin18.2 is involved in the proliferation, differentiation, and migration of tumor cells. The characteristics of Claudin18.2 (highly overexpressed in cancer cells) make it an ideal tumor-associated antigen (TAA) target. Currently, there are different treatments of biological modality targeting on Claudin18.2 in clinical trials, including monoclonal antibodies, bispecific antibodies, ADC, and CAR-T therapy.

DIMA Biotech offers a series of CLDN18.2 products for pre-clinical research needs including bioactive recombinant proteins, biosimilar benchmark antibody and rabbit monoclonal antibodies to help drug discovery. We also provide pre-validated anti-CLDN18.2 DimAb® B cell libraries, which can enable BioPharma to fish out best candidate lead antibody molecules from pre-immunized B cells in **30-45 days**.

Monoclonal antibodies against human CLDN18.2



Flow cytometry analysis with Anti-CLDN18.2 mAb (zolbetuximab, BME100075) on Expi293 cells transfected with human CLDN18.2 (Blue) or Expi293 transfected with CLDN18.1 (Red).




Flow cytometry analysis with Anti-CLDN18.2 (DM179) on Expi293 cells transfected with human CLDN18.2 (Blue) or Expi293 transfected with human CLDN18.1 (Green) or Expi293 transfected with irrelevant protein (Red).

Cat. No.	Product Name
BME100075	Anti-CLDN18.2 (zolbetuximab biosimilar, IMAB-362)
DME100179	Anti-CLDN18.2 antibody (DM179), Rabbit mAb

DimAb® Lead mAb molecules and B cell libraries

DIMA provides on-shelf pre-stocked and pre-validated hit-to-lead stage anti-CLDN18.2 antibody molecules. Our zero-waiting, zero-risk business model will not only expedite the pre-clinical development process, but also save the time and money for pharmaceutical companies.


Through *in vitro* and *in vivo* assays, pharmaceutical companies can easily identify lead drug candidate mAbs for downstream clinical studies from our DimAb® lead mAb molecules or B cell libraries. Our pre-immunized B cell libraries can provide a high flexibility for BioPharma during early hit-to-lead screening stage. They can directly apply their own assays during early screening. With DIMA's high throughput single B cloning technology, BioPharma can obtain lead antibody IgG sequence information within one week time.




Comparison of DimAb® lead discovery program and traditional lead discovery strategies

Claudin18.2, A Promising Therapeutic Target

Functional evaluation of different Claudin18.2 CAR constructs




The target cell killing efficacy of different Claudin18.2 CAR constructs




The measurement of cytokine release

CLDN18.2 Nanodisc (Cat. No. FLP100014)




ELISA assay to evaluate CLDN18.2 Nanodisc protein.
 ELISA plates were pre-coated with Flag Tag CLDN18.2 Nanodisc. Serial diluted anti-CLDN18.2 monoclonal antibody (Cat. No. BME100075) solutions were added, washed, and incubated with secondary antibody before ELISA reading.




Full-length Bioactive Human CLDN18.2 Recombinant Proteins

Cat. No.	Product Name
FLP100014	Human CLDN18.2 full length protein-synthetic nanodisc
FLP100006	Human CLDN18.2 full length protein-VLP
FLP100017	Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP)


CLDN18.2- VLP (Cat. No. FLP100006)




FACS analysis of CLDN18.2 VLP (Cat. No. FLP100006)
 A. CLDN18.2 VLP stained with Goat anti-human IgG Fc-PE secondary antibody.
 B. Negative VLP control stained with anti-CLDN18.2 antibody (Cat. No. BME100075), followed by Goat anti-human IgG Fc-PE 2nd antibody.
 C. CLDN18.2 VLP stained with anti-BCMA antibody, followed by Goat anti-human IgG Fc-PE secondary antibody.
 D. CLDN18.2 VLP stained with anti-CLDN18.2 antibody (Cat. No. BME100075), followed by Goat anti-human IgG Fc-PE 2nd antibody.




ELISA to evaluate CLDN18.2-VLP (Cat. No. FLP100006) ELISA plates were pre-coated with purified human CLDN18.2-VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (BME100075) solutions were added, washed, and incubated with 2nd antibody.



CLDN18.2-EGFP- VLP (Cat. No. FLP100017)



FACS analysis of CLDN18.2 VLP (Cat. No. FLP100017)
 A. Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP).
 B. Anti-GPRC5D-CAR-Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP).
 C. Anti-CLDN18.2-CAR-Expi293 cells were stained with biotin labeled Protein L, followed by streptavidin-APC antibody.
 D. Anti-CLDN18.2-CAR-Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP).



ELISA to evaluate CLDN18.2-EGFP-VLP (Cat. No. FLP100017) ELISA plates were pre-coated with purified human CLDN18.2-EGFP-VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (BME100075) solutions were added, washed, and incubated with 2nd antibody before ELISA reading.

For more products, please visit www.dimabio.com